Adstiladrin Side Effects

Generic name: nadofaragene firadenovec

Medically reviewed by Drugs.com. Last updated on May 25, 2024.

Note: This document provides detailed information about Adstiladrin.

Applies to nadofaragene firadenovec: urinary bladder suspension Side Effects associated with nadofaragene firadenovec. Some dosage forms listed on this page may not apply specifically to the brand name Adstiladrin.

Applies to nadofaragene firadenovec: urinary bladder suspension.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests will be needed to check for unwanted effects.

If you are a woman who can get pregnant, your doctor may do tests to make sure you are not pregnant before starting this medicine. Using this medicine while you are pregnant can harm your unborn baby. Female patients should use an effective form of birth control during treatment and for at least 6 months after the last dose. Male patients who have female partners should use an effective form of birth control during treatment and for at least 3 months after the last dose If you think you have become pregnant while using this medicine, tell your doctor right away.

Serious side effects of Adstiladrin

Along with its needed effects, nadofaragene firadenovec (the active ingredient contained in Adstiladrin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking nadofaragene firadenovec:

For healthcare professionals

Applies to nadofaragene firadenovec: intravesical suspension.

General adverse events

The most common adverse reactions reported in 10% or more patients including laboratory abnormalities in more than 15% patients, were increased glucose, instillation site discharge, increased triglycerides, fatigue, bladder spasm, micturition (urination) urgency, increased creatinine, hematuria (blood in urine), decreased phosphate, chills, dysuria, and pyrexia (fever).^[Ref]

Cardiovascular

• Common (1% to 10%): Coronary artery disease, acute coronary syndrome, atrial fibrillation, heart failure, pericarditis^[Ref]

Hematologic

• Very common (10% or more): Decreased hemoglobin (16%)^[Ref]

Metabolic

• Very common (10% or more): Increased glucose (38%), increased triglycerides (30%), increased creatinine (17%), decreased phosphate (16%)
• Common (1% to 10%): Dehydration, hypoglycemia, bile duct stone^[Ref]

Other

• Very common (10% or more): Instillation site discharge (33%), fatigue (24%), chills (16%), pyrexia (15%)
• Common (1% to 10%): Syncope, sepsis^[Ref]

Renal

• Very common (10% or more): Bladder spasm (20%), micturition urgency (19%), hematuria (17%), dysuria (16%)^[Ref]

Nervous system

• Common (1% to 10%): Brain edema^[Ref]

See also:

Further information

Adstiladrin side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer